Immuneering Appoints Former Terns CFO Andrew Gengos as Chief Financial Officer Amid Pivotal Phase 3 Pancreatic Cancer Program
Key Insights
Immuneering Corporation names Andrew Gengos, former CFO of Terns Pharmaceuticals, as its new Chief Financial Officer effective July 16, 2026.
Gengos brings over 25 years of biotech leadership experience, including roles at Amgen, Athira Pharma, and Cyteir Therapeutics, and was at Terns during its $6.7 billion acquisition by Merck.
He will oversee financial strategy and corporate development as the company advances atebimetinib (search), its lead Deep Cyclic Inhibitor, through the Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer (search).
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company, announced on June 15, 2026 the appointment of Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Gengos most recently served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for $6.7 billion. His arrival comes at a pivotal moment as Immuneering advances atebimetinib (search), its lead oncology candidate, through a global Phase 3 registrational trial in first-line pancreatic cancer (search).
"Andrew is a proven biotechnology executive with a strong track record of helping innovative companies navigate critical stages of growth and value creation," said Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering. "His experience as a CFO, business development leader, and strategic advisor will be invaluable as we advance our clinical programs and prepare for the next phase of Immuneering's growth."
A Seasoned Biotech Leader
Gengos brings more than 25 years of biotechnology leadership experience to Immuneering. Prior to Terns, he served as Chief Financial Officer and Chief Business Officer of Athira Pharma, Inc. (now LeonaBio, Inc.). Before that, he was Chief Business Officer of Cyteir Therapeutics, Inc., where he led the finance organization through the company's successful initial public offering. His earlier career includes serving as Chief Executive Officer of both ImmunoCellular Therapeutics, Ltd. and Neuraltus Pharmaceuticals, Inc., providing strategic and financial leadership across oncology and neurodegenerative disease programs.
Notably, Gengos spent eight years at Amgen Inc. (search) as Vice President of Strategy and Corporate Development, where he helped shape the company's long-term strategic priorities and business development initiatives. He began his career at Morgan Stanley and later joined McKinsey & Company, advancing from Associate to Senior Engagement Manager. Gengos holds an MBA from the UCLA Anderson School of Management and a BS in Chemical Engineering from the Massachusetts Institute of Technology.
Atebimetinib (search) and the Deep Cyclic Inhibitor Platform
At Immuneering, Gengos will oversee financial strategy, capital allocation, investor relations, business development, and corporate development activities. His appointment aligns with the company's advancement of atebimetinib (search), an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK (search).
"Atebimetinib (search) is now a Phase 3 candidate in first-line pancreatic cancer (search), supported by recently presented survival and tolerability data that are highly encouraging in a disease where new treatment options are urgently needed," said Gengos. "A growing body of data supports the potential of Immuneering's differentiated deep cyclic inhibitor technology to benefit patients with RAS, RAF, and other MAPK-driven cancers."
Immuneering's Deep Cyclic Inhibitor platform represents an entirely new category of cancer medicines designed to improve overall survival through three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability.
The company is currently conducting MAPKeeper 301, a global randomized pivotal trial evaluating atebimetinib (search) in combination with modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer (search) patients. The development pipeline also includes additional combination opportunities, a Phase 2 combination study of atebimetinib in non-small cell lung cancer (search), and preclinical stage programs.
"I believe we are in the early chapters of this compelling story and look forward to working with Immuneering's leadership team and Board to advance atebimetinib (search) through late-stage development and create value for patients and shareholders alike," Gengos added.